Who founded Bonum Therapeutics?

Bonum Therapeutics was founded by John Mulligan in 2021.

Who are Bonum Therapeutics's investors?

Bonum Therapeutics's investors include RiverVest Venture Partners, Roche Venture Fund, Vivo Capital, 3x5 Partners, Codon Capital, Digitalis Ventures.

How much funding has Bonum Therapeutics raised?

Bonum Therapeutics has disclosed $73.1M raised across 3 rounds.

Where is Bonum Therapeutics headquartered?

Bonum Therapeutics is headquartered in Seattle, US.

Bonum Therapeutics

Seattle, US · Founded 2021 · Delaware corporation · 20 employees on LinkedIn · 6 known investors

Find your way into Bonum Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Bonum Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.

Biotech Healthtech

Founders & leadership

Bonum Therapeutics was founded in 2021 by John Mulligan.

John Mulligan Founder and CEOHe has held scientific and leadership roles at multiple drug discovery and synthetic biology companies, including Darwin Molecular (where he contributed to target identification using human genetics and an osteoporosis drug target that led to Amgen's approved Evenity), Glycostasis (where he developed glucose-responsive insulin technology), and Good Therapeutics (where he served as CEO and invented core technology before its acquisition by Roche in 2022).

Neela Patel CBOExecutive Officer of Bonum Therapeutics, which develops antibody-controlled protein therapeutics for cancer and other diseases. Patel has experience in business development, including collaborations and licensing, and a track record in drug discovery and strategic planning.

Diane HollenbaughCSO

Board

Samuel Bjork Board directorPartner at Digitalis Ventures

Monique Schiersing Board directorSenior Investment Director at Roche Venture Fund

John McKearn Board directorSenior Advisor at RiverVest Venture Partners, focused on early-stage biotech

Karl Handelsman Board directorInvestor at Codon Capital

Nicholas Walrod Board of Directors2022–2026Managing Partner at American Century Private Investments

Mitchell Mutz Board director

Gaurav Aggarwal Board directorManaging Director at Vivo Capital

Samuel BlackmanBoard director

Investors · 6

RiverVest Venture Partnerslisted by RiverVest Venture PartnersSt. Louis · $500K – $3Mvia John McKearn · board

How we know: RiverVest Venture Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us

Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

3x5 PartnersreportedPortland

How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Codon CapitalreportedSan Francisco

How we know: a partner's Signal profile · funding news · Not right? Tell us

Digitalis VenturesreportedNew York · $100K – $10M

How we know: a partner's Signal profile · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$73.1M disclosed across 3 rounds · 2021–2026

▶$26.9MraisedApr 2026 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Samuel BjorkDirector
Monique SchiersingDirector
Neela PatelExecutive Officer
John McKearnDirector
Diane HollenbaughExecutive Officer
Samuel BlackmanDirector
John MulliganExecutive Officer, Director, Promoter
Karl HandelsmanDirector
Nicholas WalrodDirector
Mitchell MutzDirector
Gaurav AggarwalDirector

Offering amount: $32.3M
Amount sold: $26.9M
First sale: Apr 2026
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$45MraisedNov 2022 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Karl HandelsmanDirector
John MulliganExecutive Officer, Director, Promoter
Nicholas WalrodDirector
Monique SchiersingDirector
John McKearnDirector
Samuel BjorkDirector
Diane HollenbaughExecutive Officer
Neela PatelExecutive Officer
Mitchell MutzDirector

Offering amount: $93M
Amount sold: $45M
First sale: Nov 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.2MraisedDec 2021 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Karl HandelsmanDirector
Diane HollenbaughExecutive Officer
Neela PatelExecutive Officer
John McKearnDirector
Monique SchiersingDirector
Nicholas WalrodDirector
John MulliganExecutive Officer, Director, Promoter

Offering amount: $3.6M
Amount sold: $1.2M
First sale: Dec 2021
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Bonum Therapeutics went on to found or lead other companies.

Sam BlackmanBoard MemberFounded Day One Biopharmaceuticals John MulliganExecutive Officer, Director, PromoterFounded Good Therapeutics Mitchell MutzDirectorFounded Amplyx Pharmaceuticals

Related companies · 1

Mirum PharmaceuticalsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.

Companies working in the same space as Bonum Therapeutics.

In the news

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025 - BioSpacebiospace.com · Jun 2025

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies - BioSpacebiospace.com · Nov 2022

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies – GeekWiregeekwire.com · Nov 2022

News – Bonum Txbonumtx.com · Sep 2022

Frequently asked questions

What does Bonum Therapeutics do?: Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.
Who founded Bonum Therapeutics?: Bonum Therapeutics was founded by John Mulligan in 2021.
Who are Bonum Therapeutics's investors?: Bonum Therapeutics's investors include RiverVest Venture Partners, Roche Venture Fund, Vivo Capital, 3x5 Partners, Codon Capital, Digitalis Ventures.
How much funding has Bonum Therapeutics raised?: Bonum Therapeutics has disclosed $73.1M raised across 3 rounds.
Where is Bonum Therapeutics headquartered?: Bonum Therapeutics is headquartered in Seattle, US.